Clinical Trial Update: Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated weight loss in obese subjects treated with GW869682 or placebo three times daily for 12 weeks; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• GW869682

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obesity | Phase 2 | Status: COMPLETED